Genloxa — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Genloxa is a private, revenue-generating diagnostics laboratory focused on personalized medicine in gastroenterology and oncology. Its core offerings include proprietary 'G-tests' for fecal biomarkers (calprotectin, pancreatic elastase) and the Dose5-FU test, the only service in Poland for monitoring 5-fluorouracil levels during chemotherapy to personalize dosing. The company targets both individual patients and institutional clients like hospitals, leveraging EU-funded R&D projects to expand its test menu and laboratory capabilities. Its strategy centers on providing rapid, non-invasive diagnostics to accelerate treatment decisions and improve therapeutic outcomes.

GastroenterologyOncology

Technology Platform

Proprietary 'G-test' platform for non-invasive quantification of fecal biomarkers (calprotectin, pancreatic elastase). Specialized therapeutic drug monitoring (TDM) platform for measuring chemotherapeutic agent (5-fluorouracil) levels in blood to optimize dosing.

Opportunities

The rising prevalence of IBD and the clinical need to reduce invasive procedures drive demand for non-invasive fecal tests like calprotectin.

In oncology, the push for personalized, value-based care creates a significant opportunity for Genloxa's unique Dose5-FU therapeutic drug monitoring service to become a standard of care in Poland and potentially expand to other regions.

Risk Factors

Key risks include dependence on out-of-pocket payments or hospital budgets without established reimbursement from public healthcare, competition from larger diagnostic companies, and technological reliance on the continued widespread use of 5-FU chemotherapy in an evolving oncology treatment landscape.

Competitive Landscape

In the GI diagnostics space, Genloxa competes with other laboratories offering calprotectin and elastase tests, both locally and internationally. For its Dose5-FU service, it holds a first-mover advantage in Poland, but faces competition from established international TDM service providers and the general inertia of clinical practice against adopting new monitoring protocols.

More companies in Diagnostics & Precision Medicine →More companies in Poland →